araag2/HINT huggingface dataset:
Clinical trial NCT02301988 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ipatasertib, paclitaxel, placebo
SMILES: [H][C@](CNC(C)C)(C(=O)N1CCN(CC1)C1=NC=NC2=C1[C@]([H])(C)C[C@@]2([H])O)C1=CC=C(Cl)C=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal or postmenopausal women

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Histologically documented, Stage Ia to operable Stage IIIa, triple-negative carcinoma
             of the breast with primary tumor greter than or equal to (>/=) 1.5 centimeters (cm) in
             largest diameter (cT1-3) by MRI

          -  Adequate hematologic and organ function within 14 days before the first study
             treatment

          -  Availability of tumor tissue from formalin-fixed, paraffin-embedded (FFPE) core biopsy
             of breast primary tumor

          -  For female participants of childbearing potential, agreement to use highly effective
             form(s) of contraception for the duration of the study and for at least 6 months after
             last dose of study treatment

        Exclusion Criteria:

          -  Known human epidermal growth factor 2 (HER2)-positive, estrogen receptor
             (ER)-positive, or progesterone receptor (PgR)-positive breast cancer

          -  Any prior treatment for the current primary invasive breast cancer

          -  Participants with cT4 or cN3 stage breast tumors

          -  Metastatic (Stage IV) breast cancer

          -  Bilateral invasive breast cancer

          -  Multicentric breast cancer

          -  Any disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that contraindicates the use of an investigational drug or that may
             affect the interpretation of the results or render the participant at high risk from
             treatment complications
Clinical trial NCT02303184 (phase 2, status: completed)
Conditions: macular edema, retinal vein occlusion
ICD codes: H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120, H34.8131, H34.8132, H34.8111, H34.8121, H34.8191, H34.8331, H34.8112
Drugs: 4 mg cls-ta, sham, ivt aflibercept
SMILES: CC1=CC(O)=CC(C)=C1Cl, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of macular edema following RVO

          -  History of ME ≤ 12 months

          -  20-70 letters inclusive BCVA using ETDRS

        Exclusion Criteria:

          -  has had an IVT injection of anti-VEGF for RVO in the study eye

          -  has had a corticosteroid injection in the past 3 months in the study eye

          -  any uncontrolled ophthalmic condition in the study eye other than RVO
Clinical trial NCT02309359 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RA for at least 6 months prior to screening, and American College of
             Rheumatology (ACR) functional class I-III

          -  Subjects treated with and tolerating MTX

          -  Active RA

          -  Others as defined in the protocol

        Exclusion Criteria:

          -  Have been treated with disease-modifying antirheumatic drugs (DMARDs)/systemic
             immunosuppressives other than MTX.

          -  Have received approved or investigational biological or targeted synthetic DMARD
             therapies for RA less than 6 months prior to screening.

          -  Have a history of toxicity, non-tolerance, primary non-response or inadequate response
             to a biological therapy, or targeted synthetic DMARDs, for RA.

          -  Have received prior therapy blocking the interleukin-6 (IL-6) pathway, at any time.

          -  Others as defined in the protocol
Clinical trial NCT02309671 (phase 2, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: fe 999049, follitropin beta
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Women diagnosed with tubal infertility, unexplained infertility, infertility related
             to endometriosis stage I/II or with partners diagnosed with male factor infertility

          -  Women eligible for IVF and/or ICSI treatment

          -  Women aged 20-39 years

          -  Women with body mass index (BMI) of 17.5-32.0 kg/m2

        Exclusion Criteria:

          -  Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis
             stage III/IV

          -  Women with history of recurrent miscarriage

          -  Women with contraindications to controlled ovarian stimulation with gonadotropins

          -  Women with three or more controlled ovarian stimulation cycles
Clinical trial NCT02310802 (phase 2, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: obe001 dose 1, obe001 dose 2, obe001 dose 3, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria

          1. Women with medically indicated IVF or ICSI using her own oocytes.

          2. GnRH antagonist protocol, a single injection of hCG for triggering final follicular
             maturation and luteal phase support with vaginal micronized progesterone.

          3. Evidence of uterine contractions by transvaginal ultrasound at baseline.

        Key Exclusion Criteria

          1. Blastocyst stage or frozen-thaw transfers

          2. Clinically significant abnormalities in ECG, vital signs, physical examination or
             clinical laboratory results

          3. Severe endometriosis and/or adenomyosis or risk of ovarian hyper stimulation syndrome
Clinical trial NCT02312544 (phase 2, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: otx-tp, timolol
SMILES: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must have a documented diagnosis of ocular hypertension, open angle glaucoma
             (with or without pseudoexfoliation or pigment dispersion component).

          -  Subject has a mean baseline IOP following washout in at least 1 eye (the same eye) of

             ≥ 24mmHg at Hour 0 (T0) at Baseline Visit 1 and Baseline Visit 2 (Day 1)

          -  Subject has a mean baseline IOP following washout in at least 1 eye (the same eye) of:

             ≥ 22mmHg at (T0 + 4h) and (T0 + 8h) at Baseline Visit 1 (note: the same eye must meet
             the IOP eligibility criteria at all 4 baseline assessments)

          -  Washout IOP must be ≤ 34mmHg in each eye at all time points at the Baseline Visit 1
             and Baseline Visit 2 (Day 1)

        Exclusion Criteria:

          -  Subject with any form of glaucoma other than open angle glaucoma (with or without a
             pigment dispersion or pseudoexfoliation component).

          -  Subject with mean baseline IOP >34 mmHg in either eye at any time point during the
             Baseline Visits 1 or 2 (Day 1).

          -  Subject with a BCVA worse than 0.6 logMAR (20/80 Snellen) in either eye as measured
             using an ETDRS chart.

          -  Subject with a known or suspected allergy and/or hypersensitivity to travoprost,
             timolol, fluorescein or to any component of the study products.
Clinical trial NCT02314247 (phase 2, status: terminated)
Conditions: peripheral t-cell lymphoma (ptcl), cutaneous t-cell lymphoma (ctcl)
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: selinexor
SMILES: FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F
Reason stopped: 
    due to enrollment challenges
  
Eligibility criteria:

        Inclusion Criteria:

          -  ECOG performance status of ≤2.

          -  Relapsed or refractory disease to at least one prior systemic regimen.

          -  Measurable disease: according to International Working Group (IWG) guidelines for all
             patients with PTCL and according to CTCL Response in Skin consensus criteria for all
             patients with CTCL.

          -  Objective, documented evidence of disease progression on study entry.

        Exclusion Criteria:

          -  Known active central nervous system (CNS) lymphoma.

          -  Active graft-versus-host disease after allogeneic stem cell transplantation. At least
             4 months must have elapsed since completion of allogeneic stem cell transplantation.

          -  Unable to swallow tablets or malabsorption syndrome, disease significantly affecting
             gastrointestinal function.
Clinical trial NCT02314780 (phase 2, status: completed)
Conditions: myocardial ischemia
ICD codes: I25.6, P29.4
Drugs: heme arginate 3mg/kg, heme arginate 1mg/kg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Signed informed consent

          -  Men and women aged between 40 and 85 years (inclusive)

          -  Body mass index < 35 kg/m2

          -  Ability to communicate well with the investigator in the local language and to
             understand and comply with the requirements of the study

        Exclusion criteria (any of the following):

          -  Known hypersensitivity to the study drug or any excipients of the drug formulation

          -  Treatment with another investigational drug within 3 weeks prior to screening

          -  History or clinical evidence of any disease and/or existence of any surgical or
             medical condition, which might interfere with the absorption, distribution, metabolism
             or excretion of the study drug

          -  Severe renal failure (glomerula filtration rate < 30 ml/min)

          -  Moderately or severe impaired left ventricular function (ejection fraction < 40%)

          -  Moderately or severe impaired right ventricular function

          -  Systolic pulmonary pressure > 45 mmHg

          -  Acute or recent (<7 days) myocardial infarction

          -  Child bearing potential
Clinical trial NCT02316106 (phase 2, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: daratumumab, daratumumab, daratumumab
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of smoldering multiple myeloma (SMM) for less than 5 years

          -  Have a confirmed diagnosis of intermediate or high-risk SMM, and an Eastern
             Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

        Exclusion Criteria:

          -  Active multiple myeloma,requiring treatment as defined by the study protocol

          -  Primary systemic AL (immunoglobulin light chain) amyloidosis

          -  Prior or concurrent exposure to any of the following: approved or investigational
             treatments for SMM or/and multiple myeloma, daratumumab or other anti CD-38 therapies,
             treatment with corticosteroids with a dose greater than (>) 10 milligram (mg)
             prednisone per day or equivalent and bone-protecting agents (eg, bisphosphonates,
             denosumab) or are only allowed if given in a stable dose and for a nonmalignant
             condition, or received an investigational drug (including investigational vaccines) or
             used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1

          -  History of malignancy (other than SMM) within 3 years before the date of
             randomization, except for the following if treated and not active: basal cell or
             nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal
             carcinoma in situ of breast, or International Federation of Gynecology and Obstetrics
             (FIGO) Stage 1 carcinoma of the cervix

          -  Known chronic obstructive pulmonary disease (COPD) OR moderate or severe persistent
             asthma within the past 2 years

          -  Any concurrent medical or psychiatric condition or disease (eg, autoimmune disease,
             active systemic disease, myelodysplasia) that is likely to interfere with the study
             procedures or results, or that in the opinion of the investigator, would constitute a
             hazard for participating in this study
Clinical trial NCT02316821 (phase 2, status: completed)
Conditions: chronic kidney disease, type 2 diabetes
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: rta 402, placebo
SMILES: COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  CKD patients with type 2 diabetes mellitus

          -  Patients whose estimated GFR levels are eligible for this study

          -  Patients being treated with stable dose of angiotensin converting enzyme (ACE)
             inhibitors and/or angiotensin II receptor blocker (ARB) etc.

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus

          -  Patients with known non-diabetic renal disease

          -  Patients with a history of renal transplantation

          -  Patients with mean systolic blood pressure > 160 mmHg or diastolic blood pressure > 90
             mmHg

          -  Patients with Hemoglobin A1c > 10%

          -  Patients with cardiovascular disease specified in the study protocol etc.
Clinical trial NCT02318368 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ficlatuzumab, erlotinib, placebo
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor's decision
  
Eligibility criteria:

        Inclusion Criteria

          -  Histologically and/or cytologically confirmed primary diagnosis of Stage IV NSCLC
             (according to American Joint Committee on Cancer [AJCC] 7th edition lung cancer
             staging criteria).

          -  Measurable disease according to RECIST v.1.1.

          -  An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation.

          -  BDX004 Positive Label.

          -  Have received no prior systemic chemotherapy, immunotherapy, targeted therapy, or
             biologic therapy for metastatic NSCLC. Subjects may have previously been treated with
             postoperative adjuvant chemotherapy for early stage lung cancer or chemo radiotherapy
             for locally advanced disease provided this was completed at least 6 months prior to
             enrollment. No prior EGFR TKI therapy is allowed for any stage of NSCLC.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion
             Criteria

          -  History of severe allergic or anaphylactic reactions or hypersensitivity to
             recombinant proteins or excipients in the investigational agent or erlotinib.

          -  History of known brain metastases.

          -  Prior treatment with any other investigational drug or biologic agent within 5 half
             lives prior to randomization, or any investigational device within 2 weeks prior to
             randomization.

          -  Any unresolved toxicity from previous radiation therapy.

          -  Significant cardiovascular disease, including:

               -  Echocardiogram (ECHO) or multiple gated acquisition (MUGA) showing left
                  ventricular ejection fraction of less than 55%.

               -  Cardiac failure New York Heart Association class III or IV.

               -  Myocardial infarction, severe or unstable angina within 6 months prior to
                  randomization.

               -  History of serious ventricular arrhythmia (ie, ventricular tachycardia or
                  ventricular fibrillation).

               -  Significant thrombotic or embolic events within 3 months prior to randomization
                  (significant thrombotic or embolic events include but are not limited to stroke
                  or transient ischemic attack).

               -  Any uncontrolled or severe cardiovascular disease.

          -  History of prior malignancy within 3 years prior to randomization (except for
             adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or
             cervix, superficial bladder cancer, or early stage prostate cancer, without evidence
             of recurrence).

          -  Radiographic evidence of interstitial lung disease.
Clinical trial NCT02319759 (phase 2, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: guselkumab, ustekinumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has had Psoriatic Arthritis (PsA) for at least 6 months before the first
             administration of study drug and meet classification criteria for Psoriatic Arthritis
             (CASPAR) at Screening

          -  Had active PsA as defined by:

               1. At least 3 swollen joints and at least 3 tender joints at Screening and at
                  baseline

               2. C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram
                  (mg)/deciliter (dL) at Screening from the central laboratory

          -  Has at least 1 of the PsA subsets: distal interphalangeal joint involvement,
             polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans,
             asymmetric peripheral arthritis, or spondylitis with peripheral arthritis

          -  Has plaque psoriasis with body surface area (BSA) involvement greater than or equal to
             (>=) 3% at Screening and baseline

          -  Has active PsA despite current or previous non-biologic disease-modifying
             antirheumatic drugs (DMARD), oral corticosteroid, and/or nonsteroidal
             anti-inflammatory drug (NSAID) therapy

          -  If using methotrexate (MTX), oral corticosteroids or NSAIDs, the dose must be stable

        Exclusion Criteria:

          -  Have other inflammatory diseases that might confound the evaluations of benefit of
             guselkumab therapy, including but not limited to rheumatoid arthritis (RA), ankylosing
             spondylitis (AS), systemic lupus erythematosus, or Lyme disease

          -  Has previously received guselkumab or ustekinumab

          -  Has received more than 1 type of biologic anti-tumor necrosis factor (TNF) agent
             previously

          -  Have received infliximab (or its biosimilars) or golimumab intraveneous (IV) within 12
             weeks before the first administration of study drug

          -  Have received adalimumab (or its biosimilars), golimumab subcutaneous (SC),
             certolizumab pegol or etanercept (or its biosimilars) within 8 weeks before the first
             administration of study drug
Clinical trial NCT02322190 (phase 2, status: terminated)
Conditions: chronic graft vs. host disease, graft vs host disease, graft-versus-host disease
ICD codes: D89.810, D89.811, D89.813, D89.812
Drugs: methoxsalen
SMILES: COC1=C2OC(=O)C=CC2=CC2=C1OC=C2
Reason stopped: 
    due to slow/insufficient accrual and principal investigator left the nih
  
Eligibility criteria:

        -  INCLUSION CRITERIA:

          -  Age greater than or equal to18 years.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

          -  Subject must be also enrolled on an National Cancer Institute (NCI) allogeneic
             transplant protocol.

          -  Patients must agree to practice effective contraception (both male and female
             subjects, if the risk of conception exists)The effects of Extracorporeal Photopheresis
             (ECP) on the developing human fetus are unknown. For this reason and as well as other
             Methoxsalen used in this trial is in a class of agents that is known to be
             teratogenic, men must agree to use adequate contraception (hormonal or barrier method
             of birth control; abstinence) prior to study entry and for the duration of study
             participation, and for 4 months after the completion of study treatment. Should a
             woman become pregnant or suspect she is pregnant while her partner is participating in
             this study, she should inform her treating physician immediately.

        EXCLUSION CRITERIA:

          -  Any physical or mental condition that, in the opinion of the principal Investigator
             (PI), would cause the risk/benefit ratio of participation to be unacceptable.

          -  Inclusion of ECP in the treatment of any patient is contraindicated by any of the
             following:

          -  Unstable hemodynamics requiring vasopressors or other support measures not amenable to
             or medically appropriate for continuation during the procedure.

          -  Uncontrolled infection.

          -  Inability to maintain acceptable venous access.

          -  Uncontrolled or uncorrectable coagulopathy.

          -  Pregnant women are excluded from ECP because methoxsalen, an agent utilized for the
             study procedure, may cause fetal harm. Because there is an unknown but potential risk
             for adverse events in nursing infants secondary to treatment of the mother with
             methoxsalen, breastfeeding should be discontinued if the mother is treated with
             methoxsalen. Pregnancy will be evaluated prior to initiation of ECP.

          -  History of allergic or idiosyncratic/hypersensitivity reactions to 8-
             methoxypsoralen/psoralen compounds.

          -  History of a light-sensitive cutaneous disease

          -  Subjects with aphakia